SELLAS Life Sciences Group, Inc. (SLS)

NCM – Цена в реальном времени. Валюта: USD

5.22

-0.03 (-0.57%)

При закрытии: May 12, 2026, 4:00 PM EDT

23.04.2026

Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

SELLAS Life Sciences is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst. The company's GPS targets WT1 in AML, with prior phase 1/2 data showing a median OS of 21 months versus 5.4 months for standard therapy. Interim REGAL analysis showed fewer than 50% deceased at 13.5 months; final analysis at 80 events expected in 1H 2026.

20.04.2026

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

27.03.2026

These 16 stocks are a short seller's dream — likely losers no matter what the market does

Borrowing costs eat into trading profits. These stocks are less expensive to short.

26.03.2026

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

26.03.2026

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

20.03.2026

SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group ( NASDAQ:SLS ) is at a genuinely unusual inflection point.

19.03.2026

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events –

Видео

No Data

There is no data to display

Пресс-релизы

19.03.2026

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events –

12.03.2026

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe - - SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized - - Topline Data Expected in Q4 2026 –

14.01.2026

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into an agreement with IMPACT-AML, a European collaborative initiative dedicated to advancing innovative treatments for patients with acute myeloid leukemia (AML). Under the agreement, the IMPACT-AML network will conduct a clinical study evaluating SLS009, a highly selective CDK9 inhibitor, enabling access to multiple European clinical sites and patients.

29.12.2025

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided an update on the ongoing Phase 3 REGAL trial evaluating GPS as a potential maintenance therapy in patients with AML after second complete remission (CR2).

SELLAS Life Sciences Group, Inc. (SLS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

SELLAS Life Sciences Group, Inc. (SLS)

Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

These 16 stocks are a short seller's dream — likely losers no matter what the market does

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

These 16 stocks are a short seller's dream — likely losers no matter what the market does

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Search stocks

SELLAS Life Sciences Group, Inc. (SLS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

SELLAS Life Sciences Group, Inc. (SLS)

Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

These 16 stocks are a short seller's dream — likely losers no matter what the market does

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

These 16 stocks are a short seller's dream — likely losers no matter what the market does

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)